PT  - JOURNAL ARTICLE
AU  - HIROSE, TAKASHI
AU  - SUGIYAMA, TOMOHIDE
AU  - KUSUMOTO, SOJIRO
AU  - SHIRAI, TAKAO
AU  - NAKASHIMA, MASANAO
AU  - YAMAOKA, TOSHIMITSU
AU  - OKUDA, KENTARO
AU  - OGURA, KEIICHI
AU  - OHNISHI, TSUKASA
AU  - OHMORI, TOHRU
AU  - ADACHI, MITSURU
TI  - Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer
DP  - 2009 May 01
TA  - Anticancer Research
PG  - 1733--1738
VI  - 29
IP  - 5
4099  - http://ar.iiarjournals.org/content/29/5/1733.short
4100  - http://ar.iiarjournals.org/content/29/5/1733.full
SO  - Anticancer Res2009 May 01; 29
AB  - Background: To date, no phase II trial of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer (NSCLC) has been published. The safety and efficacy of the combination of nedaplatin and weekly paclitaxel in patients with NSCLC was examined. Patients and Methods: Patients with previously untreated NSCLC, either stage IIIB with pleural effusion or stage IV, were eligible if they had a performance status of 0 to 2, were 75 years or younger and had adequate organ function. Patients were treated with nedaplatin (80 mg/m2 on day 1) and weekly paclitaxel (90 mg/m2 on days 1, 8 and 15). Results: From March 2005 through March 2008, 47 patients (31 men and 16 women; median age, 66 years; age range, 38 to 75 years) were enrolled. The overall response rate was 53.2% (95% confidence interval, 38.1% to 67.9%). The median survival time was 13 months (range, 1 to 36 months), the 1-year survival rate was 62% and the median time to disease progression was 5 months (range, 1 to 19 months). Grade 3 to 4 hematologic toxicities included neutropenia in 38.3% of patients, thrombocytopenia in 2.1% and anemia in 23.4% . Although frequent non-hematologic toxicities were nausea, hepatic dysfunction and peripheral neuropathy, all cases were of only mild to moderate severity. Although 1 patient had grade 3 pulmonary toxicity due to drug-induced pneumonia, this patient recovered after receiving steroid therapy. Conclusion: This combination chemotherapy is effective and well tolerated and is an acceptable therapeutic option for patients with untreated advanced NSCLC.